Conversely, the proportion of apoptosis of bladder cancer cells overexpressing IGF2BP3 was significantly reduced, further confirming that IGF2BP3 knockdown can increase the sensitivity of bladder cancer to cisplatin chemotherapy (Figure 4C-D). This evidence concerns the gene IGF2BP3 and urinary bladder carcinoma.